Metformin and Aging: Where the TAME Trial Stands in 2026

A cheap diabetes pill that has been on pharmacy shelves since 1957 is somehow the most-watched drug in longevity science. Researchers think it might slow the biology of aging itself, not just lower blood sugar. The trial built to test that idea is called TAME. People have waited years for it. So where does it actually stand in 2026, and what does the data really say?

TAME is designed to test whether metformin delays age-related chronic diseases. AFAR describes a planned trial of 3,000 participants aged 65 to 79 at 14 sites, lasting six years once launched, and fundraising to launch it. This is a study plan, not evidence that metformin treats aging. ¹.

TAME stands for Targeting Aging with Metformin. It is a proposed multi-center trial of roughly 3,000 older adults, designed to see whether metformin delays the onset of a cluster of age-related diseases. As of 2026, the science is still in motion. Here is the plain version of what it is, and what it is not.

Metformin is FDA-approved to treat type 2 diabetes. It is not FDA-approved to slow aging or extend lifespan. Using it for longevity in a person without diabetes is an off-label decision, which means it sits entirely between a patient and a licensed physician who weighs that specific person's risks. This is not a protocol you should expect any brand to hand you off a menu.

Metformin carries real considerations. It can cause gastrointestinal side effects, can affect vitamin B12 levels over time, and is not appropriate for everyone, including people with certain kidney issues. None of that is a do-it-yourself calculation. There is no general dose to copy from an article, and you will not find one here. The right starting point is a conversation with a clinician who can review your labs and history.

Here is the part most marketing skips. The standard you should demand is a provider that leads with evidence, not with a pre-packaged off-label "protocol." A good provider tells you plainly when a use is off-label, names the actual risks for your body, refuses to promise an outcome a trial has not proven, and routes the decision through a licensed physician who reviews your labs and history first.

Metformin can cause gastrointestinal effects and lower vitamin B12. Its label also warns about rare, serious lactic acidosis, with risk affected by kidney function and other clinical factors. Safety is individual, and the diabetes label does not establish a longevity benefit.